Medimaps Group S.A., a global leader in AI-driven imaging for bone microarchitecture, announced the first live presentations of its new software, TBS Reveal, at the RSNA 2025 Annual Meeting in Chicago, Illinois, from November 30 to December 4. The innovative software uses artificial intelligence to analyze conventional X-ray images within existing PACS workflows, assessing both bone microarchitecture and bone mass to identify patients at risk of bone fragility. This opportunistic screening approach allows radiologists to detect potential fractures earlier and guide patients toward additional diagnostic evaluation.
Health Technology Insights: Hallmark Health Forms Executive Advisory Board
Building on its established Trabecular Bone Score (TBS) technology, Medimaps Group continues to advance AI applications in musculoskeletal health. TBS Reveal joins TBS Osteo Advanced, launched earlier in the United States, to provide radiologists with comprehensive tools for evaluating bone fragility using both X-ray and DXA imaging. TBS Reveal has been externally validated using paired DXA and X-ray data from adults aged 20 and older, achieving 90 percent accuracy, 95 percent specificity, and an 85 percent area under the curve, demonstrating robust performance in detecting bone weaknesses. The software has also been submitted to the U.S. Food and Drug Administration under the 510(k) pathway.
Health Technology Insights: TestDynamics Launches Unified Medical Imaging AI System
Univ-Prof. Dr. Didier Hans, CEO and Co-founder of Medimaps Group, explained that while conventional X-rays are among the most common imaging studies, they are rarely used to assess bone fragility despite the wealth of images already stored in PACS systems. He noted that by applying AI to these routine X-rays, TBS Reveal can identify patients at higher risk of fractures, offering a more complete picture of bone quality beyond simple density measurements. This approach empowers clinicians to intervene earlier and potentially prevent serious fractures.
Medimaps Group’s TBS technology, which analyzes grey-level texture from DXA and now X-ray images, is supported by over 1,500 scientific publications and 35 clinical guidelines. It has proven effective both as an adjunct to existing methods and as a standalone tool for fracture risk prediction, helping to identify patients who might otherwise go undiagnosed with osteoporosis.
Osteoporosis and low bone density affect millions of Americans, with the Bone Health & Osteoporosis Foundation estimating 10 million people with osteoporosis and 44 million with low bone density. This places more than 54 million adults over the age of 50 at elevated risk for fractures, contributing to an estimated $19 billion in annual healthcare costs in the U.S., projected to rise to $25.3 billion by 2025 with over three million fractures per year. Medimaps Group’s AI solutions, including TBS Reveal, aim to address this growing public health concern by enabling early detection and more effective preventive care, offering a significant opportunity to reduce fracture incidence and healthcare burdens.
Health Technology Insights: IKS Health Appoints New Chief Marketing and Chief Legal and Compliance Officers
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
